Aardvark Therapeutics, Inc. Common Stock (AARD)

• Market cap: $207M
• 1 day: 5.42%
• 5 days: -4.70%
• 1 month: -29.82%
• 3 months: -2.95%
• 6 months: -27.31%
• Year to date: -33.40%
• 1 year: -33.40%
• 5 years: -33.40%
• 10 years: -33.40%
• Sector: Healthcare
• Industry: Biotechnology

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 31

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

333% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 3

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

85% more capital invested

Capital invested by funds: $65.1M [Q1] → $121M (+$55.4M) [Q2]

30% more funds holding

Funds holding: 27 [Q1] → 35 (+8) [Q2]

0.47% more ownership

Funds ownership: 40.63% [Q1] → 41.09% (+0.47%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $19 99% upside
• Avg. target: $30 210% upside
• High target: $40 320% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Brian Abrahams	99% upside $19	Outperform Maintained	14 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	320% upside $40	Buy Initiated	30 Jun 2025